Denali(US:DNLI) Seeking Alphaยท2025-09-09 06:31Company Overview - Denali Therapeutics focuses on developing a platform to cross the blood-brain barrier, enabling the delivery of large molecules such as enzymes, antibodies, and oligonucleotides into the brain [3][4] - The company was founded approximately 10 years ago during a period when many firms were exiting the neurodegeneration space [3] Development Timeline - The first five years were dedicated to inventing the platform, while the subsequent five years were spent proving its efficacy in treating Hunter syndrome [4] - Denali aims to expand its therapeutic offerings based on initial discoveries and proof of concept achieved with blood-brain barrier-enabled therapeutics over the next five years [4] Industry Context - The current period is described as an exciting time for both Denali and the broader biotech sector, indicating a potential resurgence in interest and investment in neurodegenerative treatments [3]